Nabriva Therapeutics (NBRV) and Acura Pharmaceuticals (ACUR) are head-to-head

Nabriva Therapeutics (NASDAQ: NBRV) and Acura Pharmaceuticals (OTCMKTS: ACUR) are both small-cap medical companies, but what is the best company? We will compare the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, badyst recommendations, risk and valuation.

Analyst Recommendations

This is a summary of the current price recommendations and goals for Nabriva Therapeutics and Acura Pharmaceuticals, provided by MarketBeat.com.

Nabriva Therapeutics currently has a consensual target price of $ 17.75, suggesting a upside potential of 414.49%. Acura Pharmaceuticals has a consensus target price of $ 0.55, suggesting a potential upside of 77.42%. Given the likely rise of Nabriva Therapeutics, research badysts clearly believe that Nabriva Therapeutics is more favorable than Acura Pharmaceuticals

Insider & Institutional Ownership

62.2% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 9.3% of Acura Pharmaceuticals shares are held by institutional investors. 2.8% of Nabriva Therapeutics shares are held by insiders of the company. Comparatively, 5.6% of Acura Pharmaceuticals shares are owned by insiders of the company. Strong institutional ownership is an indication that hedge funds, endowments and large fund managers believe that a company is ready for long-term growth. Profitability

This table compares the net margins of Nabriva Therapeutics and Acura Pharmaceuticals. Net Margins Return on Equity Return on Assets Nabriva Therapeutics -600.34% -79.30% -66.97% Acura Pharmaceuticals ] -1,695.97% -1,805.00% -125.65%

Assessment and Profits

This table compares the Gross Revenues, Earnings Per Share (EPS) and the following items. evaluation of Nabriva Therapeutics and Acura Pharmaceuticals.

Acura Pharmaceuticals has a lower sales figure, but higher profits than Nabriva Therapeutics.

Risk and Volatility

Nabriva Therapeutics has a beta of 1.8, indicating that its price is 80% more volatile than the S & P 500. Comparatively, Acura Pharmaceuticals has a beta of 2.49, which indicates that its price is 149% more volatile than the S & P 500.

Abstract

Nabriva Therapeutics beats Acura Pharmaceuticals on 8 of the 11 factors compared between the two stocks

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical-stage biopharmaceutical company, is dedicated to the research and development of anti-infective agents for the treatment of infections in humans. Lefamulin, which is currently undergoing Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia, has completed for the treatment of acute bacterial skin and the skin infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin infections. In addition, he develops lefamulin for the treatment of bacterial pneumonia badociated with ventilation or bacterial pneumonia acquired in the hospital and badually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Acura Pharmaceuticals Company Profile

<img src = "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&zc=1&src=https://www.marketbeat.com /logos/acura-pharmaceuticals-inc-logo.PNG "alt =" Acura Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development and commercialization of products to combat human and animal health. abuse and abuse of drugs., a Schedule II narcotic indicated for the management of moderate to severe acute and chronic pain and Nexafed products, which are pseudoephedrine tablets and pills. Acetaminophen used as nasal decongestants in various over-the-counter cold, sinus and allergy products The company has six additional opioid products at various stages of formulation development Acura Pharmaceuticals, Inc. has collaborated and license agreements with Ega let US, Inc. and Egalet Ltd. to manufacture and market Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.

Receive News & Reviews for Nabriva Therapeutics Daily – Enter your email address below to receive a concise summary of the latest news and badyst ratings for Nabriva Therapeutics and related companies with MarketBeat's FREE daily email newsletter. com.